Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(4):672–676. doi: 10.1038/sj.bjc.6690746

CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk

O Bratt 1, Å Borg 2, U Kristoffersson 3, R Lundgren 1, Q-X Zhang 2, H Olsson 2
PMCID: PMC2362888  PMID: 10574254

Abstract

The length of the polymorphic CAG repeat in the N-terminal of the androgen receptor (AR) gene is inversely correlated with the transactivation function of the AR. Some studies have indicated that short CAG repeats are related to higher risk of prostate cancer. We performed a case–control study to investigate relations between CAG repeat length and prostate cancer risk, tumour grade, tumour stage, age at diagnosis and response to endocrine therapy. The study included 190 AR alleles from prostate cancer patients and 186 AR alleles from female control subjects. All were whites from southern Sweden. The frequency distribution of CAG repeat length was strikingly similar for cases and controls, and no significant correlation between CAG repeat length and prostate cancer risk was detected. However, for men with non-hereditary prostate cancer (n = 160), shorter CAG repeats correlated with younger age at diagnosis (P = 0.03). There were also trends toward associations between short CAG repeats and high grade (P = 0.07) and high stage (P = 0.07) disease. Furthermore, we found that patients with long CAG repeats responded better to endocrine therapy, even after adjusting for pretreatment level of prostate-specific antigen and tumour grade and stage (P = 0.05). We conclude that short CAG repeats in the AR gene correlate with young age at diagnosis of prostate cancer, but not with higher risk of the disease. Selection of patients with early onset prostate cancer in case–control studies could therefore lead to an over-estimation of the risk of prostate cancer for men with short CAG repeats. An association between long CAG repeats and good response to endocrine therapy was also found, but the mechanism and clinical relevance are unclear. © 1999 Cancer Research Campaign

Keywords: prostatic neoplasms, cancer risk, androgen receptor, genetics, epidemiology

Full Text

The Full Text of this article is available as a PDF (63.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bratt O., Kristoffersson U., Lundgren R., Olsson H. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer. 1999 Feb;35(2):272–277. doi: 10.1016/s0959-8049(98)00358-x. [DOI] [PubMed] [Google Scholar]
  2. Bratt O., Kristoffersson U., Olsson H., Lundgren R. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol. 1998;34(1):19–24. doi: 10.1159/000019672. [DOI] [PubMed] [Google Scholar]
  3. Carter B. S., Beaty T. H., Steinberg G. D., Childs B., Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3367–3371. doi: 10.1073/pnas.89.8.3367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carter B. S., Bova G. S., Beaty T. H., Steinberg G. D., Childs B., Isaacs W. B., Walsh P. C. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993 Sep;150(3):797–802. doi: 10.1016/s0022-5347(17)35617-3. [DOI] [PubMed] [Google Scholar]
  5. Chamberlain N. L., Driver E. D., Miesfeld R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994 Aug 11;22(15):3181–3186. doi: 10.1093/nar/22.15.3181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dijkman G. A., Debruyne F. M. Epidemiology of prostate cancer. Eur Urol. 1996;30(3):281–295. doi: 10.1159/000474185. [DOI] [PubMed] [Google Scholar]
  7. Giovannucci E., Stampfer M. J., Krithivas K., Brown M., Dahl D., Brufsky A., Talcott J., Hennekens C. H., Kantoff P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3320–3323. doi: 10.1073/pnas.94.7.3320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Grönberg H., Damber J. E., Jonsson H., Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol. 1994 Sep;152(3):892–895. doi: 10.1016/s0022-5347(17)32601-0. [DOI] [PubMed] [Google Scholar]
  9. Hakimi J. M., Rondinelli R. H., Schoenberg M. P., Barrack E. R. Androgen-receptor gene structure and function in prostate cancer. World J Urol. 1996;14(5):329–337. doi: 10.1007/BF00184606. [DOI] [PubMed] [Google Scholar]
  10. Hakimi J. M., Schoenberg M. P., Rondinelli R. H., Piantadosi S., Barrack E. R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res. 1997 Sep;3(9):1599–1608. [PubMed] [Google Scholar]
  11. Hardy D. O., Scher H. I., Bogenreider T., Sabbatini P., Zhang Z. F., Nanus D. M., Catterall J. F. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab. 1996 Dec;81(12):4400–4405. doi: 10.1210/jcem.81.12.8954049. [DOI] [PubMed] [Google Scholar]
  12. Hayes R. B., Liff J. M., Pottern L. M., Greenberg R. S., Schoenberg J. B., Schwartz A. G., Swanson G. M., Silverman D. T., Brown L. M., Hoover R. N. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer. 1995 Jan 27;60(3):361–364. doi: 10.1002/ijc.2910600315. [DOI] [PubMed] [Google Scholar]
  13. Ingles S. A., Ross R. K., Yu M. C., Irvine R. A., La Pera G., Haile R. W., Coetzee G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997 Jan 15;89(2):166–170. doi: 10.1093/jnci/89.2.166. [DOI] [PubMed] [Google Scholar]
  14. Irvine R. A., Yu M. C., Ross R. K., Coetzee G. A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995 May 1;55(9):1937–1940. [PubMed] [Google Scholar]
  15. Kazemi-Esfarjani P., Trifiro M. A., Pinsky L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet. 1995 Apr;4(4):523–527. doi: 10.1093/hmg/4.4.523. [DOI] [PubMed] [Google Scholar]
  16. Keetch D. W., Rice J. P., Suarez B. K., Catalona W. J. Familial aspects of prostate cancer: a case control study. J Urol. 1995 Dec;154(6):2100–2102. [PubMed] [Google Scholar]
  17. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E., Fischbeck K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991 Jul 4;352(6330):77–79. doi: 10.1038/352077a0. [DOI] [PubMed] [Google Scholar]
  18. Lesko S. M., Rosenberg L., Shapiro S. Family history and prostate cancer risk. Am J Epidemiol. 1996 Dec 1;144(11):1041–1047. doi: 10.1093/oxfordjournals.aje.a008876. [DOI] [PubMed] [Google Scholar]
  19. Lubahn D. B., Brown T. R., Simental J. A., Higgs H. N., Migeon C. J., Wilson E. M., French F. S. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9534–9538. doi: 10.1073/pnas.86.23.9534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Monroe K. R., Yu M. C., Kolonel L. N., Coetzee G. A., Wilkens L. R., Ross R. K., Henderson B. E. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med. 1995 Aug;1(8):827–829. doi: 10.1038/nm0895-827. [DOI] [PubMed] [Google Scholar]
  21. Narod S. A., Dupont A., Cusan L., Diamond P., Gomez J. L., Suburu R., Labrie F. The impact of family history on early detection of prostate cancer. Nat Med. 1995 Feb;1(2):99–101. doi: 10.1038/nm0295-99. [DOI] [PubMed] [Google Scholar]
  22. Rinker-Schaeffer C. W., Partin A. W., Isaacs W. B., Coffey D. S., Isaacs J. T. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate. 1994 Nov;25(5):249–265. doi: 10.1002/pros.2990250505. [DOI] [PubMed] [Google Scholar]
  23. Ross R. K., Pike M. C., Coetzee G. A., Reichardt J. K., Yu M. C., Feigelson H., Stanczyk F. Z., Kolonel L. N., Henderson B. E. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998 Oct 15;58(20):4497–4504. [PubMed] [Google Scholar]
  24. Schaid D. J., McDonnell S. K., Blute M. L., Thibodeau S. N. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet. 1998 Jun;62(6):1425–1438. doi: 10.1086/301862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Smith J. R., Freije D., Carpten J. D., Grönberg H., Xu J., Isaacs S. D., Brownstein M. J., Bova G. S., Guo H., Bujnovszky P. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996 Nov 22;274(5291):1371–1374. doi: 10.1126/science.274.5291.1371. [DOI] [PubMed] [Google Scholar]
  26. Stanford J. L., Just J. J., Gibbs M., Wicklund K. G., Neal C. L., Blumenstein B. A., Ostrander E. A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 1997 Mar 15;57(6):1194–1198. [PubMed] [Google Scholar]
  27. Tut T. G., Ghadessy F. J., Trifiro M. A., Pinsky L., Yong E. L. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 1997 Nov;82(11):3777–3782. doi: 10.1210/jcem.82.11.4385. [DOI] [PubMed] [Google Scholar]
  28. Whittemore A. S., Wu A. H., Kolonel L. N., John E. M., Gallagher R. P., Howe G. R., West D. W., Teh C. Z., Stamey T. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol. 1995 Apr 15;141(8):732–740. doi: 10.1093/oxfordjournals.aje.a117495. [DOI] [PubMed] [Google Scholar]
  29. Xu J., Meyers D., Freije D., Isaacs S., Wiley K., Nusskern D., Ewing C., Wilkens E., Bujnovszky P., Bova G. S. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998 Oct;20(2):175–179. doi: 10.1038/2477. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES